Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hoadley

Showing results (121-130 of 191) with videos related to

Pageof 20
Sort By:
Health Technology Assessment (Winchester, England)|February 28, 2012
Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE)M J Crawford, H Killaspy, T R Barnes, et al.
JNCI Cancer Spectrum|January 14, 2021
Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological FeaturesHalei C Benefield, Katherine E Reeder-Hayes, Hazel B Nichols, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2023
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)Holly Tovey, Orsolya Sipos, Joel S Parker, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 29, 2018
PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study CohortsKevin H Kensler, Venkat N Sankar, Jun Wang, et al.
Nature Communications|November 5, 2022
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancerJeffrey S Damrauer, Wolfgang Beckabir, Jeff Klomp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2020
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast CancerAranzazu Fernandez-Martinez, Ian E Krop, David W Hillman, et al.
JAMA Oncology|January 5, 2023
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA TrialsAranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, et al.
Oncoimmunology|November 3, 2018
Tumor mutational burden is a determinant of immune-mediated survival in breast cancerAlexandra Thomas, Eric D Routh, Ashok Pullikuth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2010
Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell typesMatthew D Wilkerson, Xiaoying Yin, Katherine A Hoadley, et al.
Plos Biology|December 11, 2020
In silico APC/C substrate discovery reveals cell cycle-dependent degradation of UHRF1 and other chromatin regulatorsJennifer L Franks, Raquel C Martinez-Chacin, Xianxi Wang, et al.
Pageof 20

Showing results (121-130 of 191) with videos related to

Sort By:
Pageof 20
Health Technology Assessment (Winchester, England)|February 28, 2012
Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE)M J Crawford, H Killaspy, T R Barnes, et al.
JNCI Cancer Spectrum|January 14, 2021
Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological FeaturesHalei C Benefield, Katherine E Reeder-Hayes, Hazel B Nichols, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2023
Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727)Holly Tovey, Orsolya Sipos, Joel S Parker, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 29, 2018
PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study CohortsKevin H Kensler, Venkat N Sankar, Jun Wang, et al.
Nature Communications|November 5, 2022
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancerJeffrey S Damrauer, Wolfgang Beckabir, Jeff Klomp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 23, 2020
Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast CancerAranzazu Fernandez-Martinez, Ian E Krop, David W Hillman, et al.
JAMA Oncology|January 5, 2023
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA TrialsAranzazu Fernandez-Martinez, Tomás Pascual, Baljit Singh, et al.
Oncoimmunology|November 3, 2018
Tumor mutational burden is a determinant of immune-mediated survival in breast cancerAlexandra Thomas, Eric D Routh, Ashok Pullikuth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2010
Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell typesMatthew D Wilkerson, Xiaoying Yin, Katherine A Hoadley, et al.
Plos Biology|December 11, 2020
In silico APC/C substrate discovery reveals cell cycle-dependent degradation of UHRF1 and other chromatin regulatorsJennifer L Franks, Raquel C Martinez-Chacin, Xianxi Wang, et al.
Pageof 20